Loading…
Medicamen Biotech Limited announced the outcome of its Board Meeting held on April 24, 2025. The Board approved and carried out the following preferential allotments:
Consequent to the equity share allotment, the Paid-up Equity Share Capital of the Company has increased to ₹13,56,28,200 (₹13.56 crore), comprising 1,35,62,820 equity shares of face value ₹10 each.
Medicamen Biotech Limited's Board of Directors, in a meeting held on April 24, 2025, approved and allotted shares and warrants on a preferential basis:
Consequent to the allotment of equity shares, the paid-up equity share capital of the company increased to ₹13,56,46,000, comprising 1,35,64,600 equity shares of ₹10 each.
Medicamen Biotech Limited has signed a contract with XGX Pharma, a European company, for CDMO services.
Medicamen Biotech Limited announced its strategic expansion into key regulated markets and released its vision for 2030. Key highlights include:
Medicamen has invested over ₹170 crores in upgrading infrastructure. The company's vision includes obtaining product registrations and establishing strategic partnerships in global markets, expanding its proprietary brand in India, leveraging R&D for CDMO capabilities, and enhancing its product portfolio. MBL has transitioned from a domestic government business to a global supplier, expanding its presence in ROW and emerging markets. With EU and USFDA plant approvals, the company is now well-positioned to access regulated markets like the US, EU, Australia and Canada. The company's R&D investment is ₹50 crores. MBL has launched Medicamen Life Sciences Ltd. to market brands in chronic segments, especially Cardio-vascular & Diabetes.